A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Where Summit Therapeutics ( SMMT -7.92%) falls on that spectrum is a big question mark right now. It has been among the hottest healthcare stocks to own over the past 12 months, as its valuation has ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare ...

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.